The company operates under the direction of the Managing Director, Dr David Hutchinson. With its focus on antimalarial chemotherapy, Dr Hutchinson brings a wealth of experience gained from the successful development of atovaquone and proguanil (Malarone) as the first antimalarial to have originated from the pharmaceutical industry in over thirty years.
Qualifying in medicine at St Bartholomew’s Hospital, London in 1962 with the degree of MB.BS, he gained a Diploma in Tropical Medicine and Hygiene from the Liverpool School of Tropical Medicine in 1971. He joined the Wellcome Research Laboratories in 1974 as a Clinical Research Physician with responsibility for anti-parasitic chemotherapy, reflecting the Company’s longstanding interest in developing effective, safe and affordable treatments for protozoal and helminthic infections. His major contribution was in identifying rapid metabolic degradation as the cause of the failure of the hydroxynaphthoquinones when administered to human subjects leading to the synthesis of atoavquone and its subsequent development in combination with proguanil.
Following the merger of the Wellcome Foundation and GlaxoSmithKIine, he acted as Consultant to the newly formed company of GlaxoWellcome during the international registration of Malarone, co-authoring a number of key publications at the same time.
He has been at the forefront of the clinical development of fosmidomycin since its inception as a candidate antimalarial in 1999 while maintaining an active role in clinical medicine.